Nationales Centrum für Tumorerkrankungen Dresden

Name

Nationales Centrum für Tumorerkrankungen Dresden

Legal name

Nationales Centrum für Tumorerkrankungen Dresden (NCT/UCC Dresden)

Website

https://nct-dresden.de

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Comprehensive Cancer Care and Oncology Research Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), General Medical and Surgical Hospitals (622110), Medical Laboratories (621511), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215)

SIC

Services-Health Services (8000), Services-General Medical & Surgical Hospitals, Nec (8062), Services-Specialty Outpatient Facilities, Nec (8093), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Central Laboratory Services (Core Lab Operations) (HLAGAEAA), Oncology Telemedicine Platforms (HLALAGAH), Gynecologic Oncology & Women’s Cancer Centers (HLAFAJAK), Surgical Oncology (HLAKAFAG), Thoracic (Lung) Oncology (HLAKAFAL), Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Comprehensive cancer care
• Clinical oncology research
• Molecular tumor diagnostics
• Translational cancer medicine
• Oncology clinical trials

Headquarters

HQ city

Dresden

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Public Healthcare Reimbursement (GKV): As a university hospital-based cancer center in Germany, NCT/UCC Dresden receives reimbursement for clinical services through the statutory health insurance system (GKV/Gesetzliche Krankenversicherung) and private insurers. Revenue is generated from patient treatments, diagnostic services, and hospital stays.
2. Research Grants and Structural Funding: NCT/UCC Dresden receives structural funding from German Cancer Aid (Deutsche Krebshilfe) and institutional support from its four founding partners (DKFZ, UKD, TU Dresden, HZDR). Additional funding comes from competitive research grants (DFG, BMBF, EU, G-BA).
3. Clinical Trial Conduct: The center conducts sponsored clinical trials for pharmaceutical companies, biotech firms, and academic consortia, generating revenue through study coordination, site fees, and patient enrollment.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

Nationales Centrum für Tumorerkrankungen Dresden (NCT/UCC Dresden) is a comprehensive cancer center that integrates patient care with translational research. It delivers multidisciplinary oncology services across 11 organ cancer centers, conducts early-phase and registry clinical trials, performs molecular diagnostics (whole-genome and RNA sequencing), and offers the NCT MASTER program for molecularly guided personalized therapy. The center is jointly operated by DKFZ, University Hospital Carl Gustav Carus Dresden, TU Dresden, and HZDR.

Product overview

NCT/UCC Dresden is a comprehensive cancer center jointly operated by the German Cancer Research Center (DKFZ), University Hospital Carl Gustav Carus Dresden, TU Dresden Faculty of Medicine, and Helmholtz-Zentrum Dresden-Rossendorf. The center combines research and patient care through multiple interconnected services: organ-specific cancer treatment centers (breast, gynecological, skin, pediatric, head/neck, neuro-oncology, sarcoma, uro-oncology, visceral oncology), the NCT MASTER-Program for molecular cancer stratification, clinical trials infrastructure including an Early Clinical Trial Unit, telemedicine services for remote patient monitoring, and a Prevention Center. The center integrates laboratory research with clinical practice to deliver personalized, evidence-based cancer treatment based on the latest scientific findings.

Differentiator

Problem solved

Functional benefit

Products and services

• Organ Cancer Centers Specialized multidisciplinary treatment centers covering 11 tumor types: breast, gynecological, skin, pediatric oncology, head and neck, neuro-oncology, sarcoma, uro-oncology, visceral oncology, small intestine tumors/NETs, and hematologic neoplasms. For cancer patients across all disease stages.
• NCT MASTER-Programm Molecular stratification program for somatic and hereditary cancers that provides comprehensive genomic profiling (whole-genome sequencing, RNA sequencing) and personalized therapy recommendations for patients with rare or advanced cancers.
• Clinical Trials Services Oncology clinical trial services operated through the Early Clinical Trial Unit (ECTU), covering first-in-human and early-phase trials, an extended trials catalog, and registry trials. Germany's largest study site for certain cancer types, available to patients via physician referral.
• Telemedicine Services for Pediatric Oncology Remote care and monitoring services for pediatric oncology patients during intensive chemotherapy phases. For children with cancer and their families to reduce hospital visits and travel burden.
• NCT/UCC Prevention Center Cancer prevention programs including the MotivA program for motivation in active everyday life, skin cancer prevention in preschools and schools, nutritional counseling, sport therapy, and the 'Active Living with Cancer' lifestyle program.
• Comprehensive Cancer Treatment Services Integrated cancer treatment services delivered through the outpatient clinic (Ambulanz), day care unit (Tagesklinik), and multidisciplinary tumor boards. Services include surgery, radiation therapy, medication therapy, molecular diagnostics, second opinions, and access to clinical trials.

Quantifiable outcome

• Telemedicine in pediatric oncology: 337 hospital visits and ~42,000 km of travel saved for 55 enrolled children during intensive chemotherapy phases.
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Partnerships

Eleven partnerships are on record, tiered core founding partner, collaborative partner and core partner.

• German Cancer Research Center (DKFZ)core founding partnerStrategic or Co-development PartnerDKFZ is one of four founding institutional partners of NCT/UCC Dresden. The DKFZ provides research leadership, scientific expertise, and is one of the NCT sites (alongside Heidelberg) combining DKFZ research with university hospital care. DKFZ is Germany's largest biomedical research institution with over 3,000 employees and is 90% funded by the Federal Ministry of Education and Research.
• University Hospital Carl Gustav Carus Dresdencore founding partnerStrategic or Co-development PartnerThe University Hospital Carl Gustav Carus Dresden is the hosting institution for NCT/UCC Dresden, providing clinical facilities, staff, and patient care infrastructure. It is a public-law institution with approximately 1,295 beds, 860 doctors, and 1,860 nurses, serving as the largest hospital in eastern Saxony.
• Carl Gustav Carus Faculty of Medicine, TU Dresdencore founding partnerStrategic or Co-development PartnerThe Medical Faculty of TU Dresden is a founding partner providing academic leadership, research supervision, and connecting clinical care with university-level research. Dresden University Medicine employs staff from 73 nations.
• Helmholtz-Zentrum Dresden-Rossendorf (HZDR)core founding partnerStrategic or Co-development PartnerHZDR is a founding partner contributing research expertise in energy, health, and matter. It focuses on better visualization, characterization, and effective treatment of cancer, and operates large research infrastructures. HZDR employs approximately 1,200 people including 500 researchers and 170 PhD students.
• Brandenburg University of Technology Cottbus-Senftenberg (BTU)collaborative partnerStrategic or Co-development PartnerBTU collaborated with NCT/UCC Dresden on the 'Active Living with Cancer' (Aktiv Leben mit Krebs) program, providing health sciences expertise. The program offers scientifically based lifestyle recommendations for cancer patients in areas with few available courses.
• DKMS (Deutsche Knochenmarkspenderdatei)collaborative partnerStrategic or Co-development PartnerDKMS served as pharmaceutical sponsor for the ASAP clinical trial on AML stem cell transplantation, providing organizational and financial support. DKMS is an international non-profit organization dedicated to blood cancer treatment with over 11.5 million registered donors.
• Study Alliance Leukemia (SAL)collaborative partnerStrategic or Co-development PartnerSAL is a German consortium of 46 treatment centers collecting AML patient data that supported multiple NCT/UCC Dresden-led clinical trials including the time-to-treatment study (2,263 patients) and stem cell transplant trials.
• European Society for Medical Oncology (ESMO)collaborative partnerStrategic or Co-development PartnerESMO's 'Real World Data & Digital Health Task Force' convened an international expert panel, including NCT/UCC Dresden researchers, to develop guidelines for the safe use of large language models (LLMs) in oncology.
• EKFZ for Digital Health (Else Kröner-Fresenius Center)collaborative partnerStrategic or Co-development PartnerEKFZ for Digital Health, a TUD Dresden center, collaborated with NCT/UCC Dresden on AI/LLM safety guidelines in oncology. Led by Prof. Jakob N. Kather, researchers contributed to international ESMO guidelines.
• NCT Heidelbergcore partnerStrategic or Co-development PartnerNCT Heidelberg is the sister NCT site, jointly operated by DKFZ and Heidelberg University Hospital. NCT sites share common goals of developing into top international centers for patient-oriented cancer research and share best practices across sites.
• German Cancer Consortium (DKTK)collaborative partnerStrategic or Co-development PartnerNCT/UCC Dresden participates in DKTK (German Consortium for Translational Cancer Research), one of six German Centers for Health Research, maintaining translational centers at seven university partner locations.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Others

• DKFZ (German Cancer Research Center): Founding partner of NCT/UCC Dresden and Germany's largest biomedical research institution. Not a direct competitor but the key upstream research partner and enabler of Dresden's translational capabilities.

Direct peers

• Charité Comprehensive Cancer Center (CCCC): Comprehensive Cancer Center at Charité Berlin, one of Germany's leading university hospital-based oncology centers. Comparable scope, structure, and integration of research with clinical care in the German university hospital system.
• University Hospital LMU Munich - Comprehensive Cancer Center: Major German university hospital cancer center with comprehensive oncology services, multidisciplinary tumor boards, and translational research infrastructure. Comparable in scope and clinical trial capacity.
• University Hospital Cologne - CIO: Center for Integrated Oncology (CIO) Cologne-Bonn is a major German comprehensive cancer center with comparable translational research focus and clinical trial infrastructure.
• University Hospital Frankfurt - University Cancer Center (UCT): University Cancer Center Frankfurt (UCT) provides comparable comprehensive oncology services including organ cancer centers, clinical trials, and translational research within a major German university hospital.
• NCT Heidelberg (National Center for Tumor Diseases Heidelberg): Sister NCT site jointly operated by DKFZ and Heidelberg University Hospital. Direct peer with identical translational research model, founding DKFZ partnership, and shared best practices across the German NCT network.
• University Hospital Hamburg-Eppendorf - UCCH: University Cancer Center Hamburg (UCCH) is a leading German comprehensive cancer center offering comparable integrated oncology care, research programs, and DKTK affiliation.

Broad incumbents

• Karolinska Comprehensive Cancer Center: Swedish comprehensive cancer center affiliated with Karolinska Institute, comparable in translational research model and university hospital integration. European peer in academic oncology.
• Gustave Roussy Institute: Leading European comprehensive cancer center in France, conducting comparable translational research, early-phase clinical trials, and personalized oncology programs. International benchmark for academic cancer center scale.
• Vanderbilt-Ingram Cancer Center: NCI-designated Comprehensive Cancer Center with comparable translational research and clinical trial infrastructure, used as an international benchmark for academic cancer center operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/NCT_UCC_DD
• YouTubeyoutube.com/channel/UCHs8-759EkiNIVoE67b9ISg
• LinkedInlinkedin.com/company/nationales-centrum-f%C3%BCr-tumorerkrankungen-dresden

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nationales Centrum für Tumorerkrankungen Dresden